| Pharmaceutical Practices and Patient Outcomes | Lifetime | 83 | GB 9 | 98.92 |
| Pharmaceutical Economics and Policy | Lifetime | 57 | GB 8 | 98.77 |
| Antibiotic Use and Resistance | Lifetime | 108 | GB 9 | 99.20 |
| Pharmaceutical studies and practices | Lifetime | 144 | GB 13 | 98.53 |
| Pharmaceutical industry and healthcare | Lifetime | 42 | GB 2 | 97.68 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 689 | GB 117 | 98.44 |
| Biosimilars and Bioanalytical Methods | Lifetime | 116 | GB 9 | 97.55 |
| Patient Satisfaction in Healthcare | Lifetime | 220 | GB 29 | 97.54 |
| Pneumonia and Respiratory Infections | Lifetime | 717 | GB 75 | 97.72 |
| Economic and Financial Impacts of Cancer | Lifetime | 338 | GB 24 | 96.34 |
| Medication Adherence and Compliance | Lifetime | 258 | GB 18 | 96.29 |
| Public Health in Brazil | Lifetime | 460 | GB 4 | 94.76 |
| Pharmaceutical Quality and Counterfeiting | Lifetime | 67 | GB 7 | 91.58 |
| Pharmacovigilance and Adverse Drug Reactions | Lifetime | 392 | GB 38 | 90.63 |
| Diverse Scientific Research Studies | Lifetime | 661 | GB 13 | 74.49 |
| Patient Satisfaction in Healthcare | 2021-2025 | 1 | GB 1 | 99.45 |
| Antibiotic Use and Resistance | 2021-2025 | 7 | GB 1 | 99.45 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 8 | GB 3 | 99.00 |
| Pharmaceutical Economics and Policy | 2021-2025 | 10 | GB 2 | 98.56 |
| Pneumonia and Respiratory Infections | 2021-2025 | 39 | GB 6 | 98.75 |
| Pharmaceutical studies and practices | 2021-2025 | 28 | GB 2 | 97.49 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 184 | GB 29 | 97.84 |
| Global Maternal and Child Health | 2021-2025 | 160 | GB 15 | 97.63 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 197 | GB 7 | 97.29 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 62 | GB 2 | 95.87 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 260 | GB 30 | 96.19 |
| COVID-19 epidemiological studies | 2021-2025 | 798 | GB 97 | 91.55 |
| Pharmaceutical Quality and Counterfeiting | 2021-2025 | 20 | GB 4 | 87.40 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 469 | GB 21 | 88.82 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 502 | GB 20 | 87.82 |
| Nosocomial Infections in ICU | 2021-2025 | 284 | GB 13 | 84.89 |
| Public Health in Brazil | 2021-2025 | 286 | GB 1 | 84.87 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 794 | GB 34 | 82.16 |
| Diverse Scientific Research Studies | 2021-2025 | 191 | GB 4 | 75.97 |
| Healthcare Systems and Reforms | 2021-2025 | 942 | GB 74 | 75.54 |
| Neonatal and Maternal Infections | 2021-2025 | 469 | GB 41 | 71.32 |
| Healthcare Systems and Technology | 2021-2025 | 517 | GB 68 | 64.02 |
| Pharmaceutical industry and healthcare | 2021-2025 | 197 | GB 18 | 64.84 |
